Early View

Original article

Treatment with Isoniazid or Rifampin for Latent Tuberculosis Infection: Population-Based Study of Hepatotoxicity, Completion, and Costs

Lisa A. Ronald, J. Mark FitzGerald, Gillian Bartlett-Esquilant, Kevin Schwartzman, Andrea Benedetti, Jean-François Boivin, Dick Menzies

Treatment with Isoniazid or Rifampin for Latent Tuberculosis Infection: Population-Based Study

of Hepatotoxicity, Completion, and Costs

Lisa A Ronald[1,2]; J Mark FitzGerald[2,3]; Gillian Bartlett-Esquilant[4]; Kevin Schwartzman[1,5,6];

Andrea Benedetti[1,5,6]; Jean-François Boivin[1]; Dick Menzies[1,5]

1. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

2. Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada

3. Institute for Heart and Lung Health, University of British Columbia, Vancouver, Canada

4. Department of Family Medicine, McGill University, Montreal, Quebec, Canada

5. Respiratory Epidemiology and Clinical Research Unit, and McGill International TB Centre, Montreal Chest Institute, Montreal, Quebec, Canada

6. Department of Medicine, McGill University, Montreal, Quebec, Canada

Corresponding author:

Dr. Dick Menzies

Respiratory Epidemiology and Clinical Research Unit (RECRU)/ Montreal Chest Institute

Room 3D.58, 5020 de Maisonneuve W,

Montreal, QC, Canada

H3H 2R9

Tel: 1-514-934-1934 ext 32128

Fax: 1-514-843-2083

Email: Dick.Menzies@Mcgill.ca

Key message: The use of 4 months Rifampin (4R) instead of 9 months of Isoniazid (9H) for treatment of latent tuberculosis infection is supported by our findings of lower risk of severe hepatotoxicity, better completion, and lower adjusted direct costs with 4R

ABSTRACT

Background

Clinical trials suggest less hepatotoxicity and better adherence with 4 months rifampin (4R) versus 9 months isoniazid (9H) for treating latent tuberculosis infection (LTBI). Our objectives were to compare frequencies of severe hepatic adverse events and treatment completion, and direct health system costs of LTBI regimens 4R and 9H, in the general population of the province of Quebec, Canada, using provincial health administrative data.

Methods

Our retrospective cohort included all patients starting rifampin or isoniazid regimens between 2003 and 2007. We estimated hepatotoxicity from hospitalization records, treatment completion from community pharmacy records, and direct costs from billing records and fee schedules. We compared rifampin to isoniazid using logistic (hepatotoxicity), log-binomial (completion), and gamma (costs) regression, with adjustment for age, co-morbidities, and other confounders.

Results

10,559 individuals started LTBI treatment (9684 isoniazid; 875 rifampin). Rifampin patients were older with more baseline co-morbidities. Severe hepatotoxicity risk was higher with isoniazid (n=15) than rifampin (n=1), adjusted OR=2.3 (95%CI: 0.3,16.1); there were 2 liver transplants and 1 death with isoniazid and none with rifampin. Overall, patients without co-morbidities had lower hepatotoxicity risk (0.1% vs 1.0%). 4R completion (53.5%) was higher than 9H (36.9%), adjusted RR=1.5 (95%CI:1.3,1.7). Mean costs per patient were lower for rifampin than isoniazid: adjusted Cost Ratio=0.7 (95%CI:0.5,0.9).

Conclusion

Risk of severe hepatotoxicity and direct costs were lower, and completion was higher, for 4R than 9H, after adjustment for age and co-morbidities. Severe hepatotoxicity resulted in death or liver transplant in three patients receiving 9H, compared to no patients receiving 4R.

INTRODUCTION

Treatment for latent tuberculosis infection (LTBI) is a key component of TB prevention, particularly in low-TB incidence countries[1]. The recommended LTBI treatment regimen is 9 months daily isoniazid (9H) in the US[2] and Canada[3], and 6-9 months isoniazid in the European Union[4]. However, hepatotoxicity concerns and low completion with isoniazid have prompted trials of shorter duration regimens.

A randomized controlled trial of four months rifampin (4R) reported comparable efficacy to 9H, but with fewer adverse events and higher adherence[5-7]. However, while the drug cost of rifampin is often higher than isoniazid, costs of monthly monitoring and unplanned visits to manage drug-related adverse events are higher with the 9H than the 4R regimen[8]. Further, most studies of 4R have been randomized trials[5-7] or single-clinic observational studies[9-13]. These studies may overestimate adherence and underestimate drug-related adverse event rates and costs occurring in 'real-world' settings with more diverse provider types and patient populations, including older patients and those with co-morbidities[14].

In Quebec, Canada, approximately 99% of permanent residents are beneficiaries of the provincial health insurance plan, and since 1997, all TB drugs have been paid for by this plan for all Quebec residents[15]. This means that information from this provincial health insurance plan is essentially complete for all persons receiving TB drugs in the province. Our objectives were to

use this population-wide data to compare frequencies of severe hepatic adverse events, treatment completion, and direct health system costs of 4R and 9H, in all persons receiving these two regimens in Quebec between 2003 and 2007.

METHODS

Data source and population

A retrospective cohort was identified of all individuals starting LTBI treatment with isoniazid or rifampin between 2003 and 2007 in Quebec. During these years, 9H was considered the primary LTBI regimen, and 4R was considered an alternative regimen. The cohort was extracted from the provincial public health insurance (Régie de l'assurance maladie du Québec (RAMQ)) database, including physician billing records, hospitalizations, drug plan coverage, and drugs dispensed.

The first RAMQ drug dispensation record for isoniazid or rifampin was identified as a patient's '*index date'*. We extracted data starting three years before, and ending three years after, the index date, or ending earlier with death or study period end (October 18, 2009). We excluded rifampin patients from the cohort when prescribed for other known indications (Appendix-Table 1).

Definitions of exposure and outcome

We defined the '*LTBI treatment period'* as starting on each patient's index date and ending 30 days after the last TB drug was dispensed (ie. date last drug dispensed+number of days dispensed+30 days). The main exposure variable was the LTBI regimen the patient initially started (isoniazid or rifampin). We identified LTBI regimen switches when a change in regimen occurred 7 or more days after the initial regimen dispensation date, with permanent

discontinuation of the initial regimen. When patients switched from one regimen to another, we calculated the number of doses dispensed for the first regimen only and ended the LTBI treatment period window at 30 days after the last dispensation of the initial drug. . Patients dispensed isoniazid and rifampin concurrently, when not identified as a regimen switch, were excluded from the cohort definition (n=81).

We defined '*LTBI treatment completion*' as 120 doses dispensed within 6 months (4R), and 270 doses within 12 months (9H)[2]. We identified a *'severe hepatic adverse event'* as any hospital admission occurring within the LTBI treatment period, with an incident ICD9/10 diagnostic code or procedure code indicating a hepatotoxic event[16] followed by permanent drug discontinuation (see Appendix-Table 1). If any of the same codes for liver disease also occurred in the year before start of LTBI treatment, we did not count this patient as having a severe hepatic adverse event related to LTBI treatment.

Health service events included emergency department (ED) visits, hospitalizations, hospital day procedures, physician visits, and drugs dispensed. Health service costs were tabulated to the end of LTBI treatment or to the recommended time limit for each regimen (ie. 12 months (9H) and 6 months (4R)), whichever was earliest. Among patients whose LTBI treatment ended due to a severe hepatotoxic adverse event or regimen switch, costs were included up to 30 days after the last dispensation date of the initial drug (ie. if a regimen was switched on January 1st, costs were tabulated to January 30th). Costs were estimated using 2011 Canadian dollars, representing the final follow-up year. Direct costs were estimated using fees paid by RAMQ (as reported in the RAMQ database), or where not available (eg., hospitalizations, ED visits, and day procedures), fee schedules were used[17, 18] (Appendix-Table 2).

Definitions of confounders

Potential confounder variables were identified based on *a priori* hypotheses about factors associated with LTBI treatment outcomes[10, 19-21]. Variables were extracted at each patient's index date, including treatment initiation year, age group (0-19, 20-34, 35-49, 50-64, 65-74, and ≥80 years), sex, pre-treatment co-morbidities, and treating physician type.

We measured co-morbidities in multiple ways. First, we identified when a cohort member was hospitalized for any reason in the year before treatment start (considered as a general indicator of baseline co-morbidity). Second, we calculated the Charlson-Deyo co-morbidity score for each patient in the year before treatment start as an indicator of general co-morbidity severity[22]. The Charlson-Deyo score is a validated risk predictor of one-year mortality often used as an indicator of co-morbidity severity, and is calculated using diagnostic codes in hospital discharge records. Third, we identified when individuals had specific TB-related medical risk factors (HIV/AIDS, diabetes, cancer, renal disease, solid organ transplant, silicosis, and treatment with TNF-alpha inhibitors)[3], liver disease, or a psychiatric diagnosis when there were one or more relevant ICD9/10 diagnostic codes or procedure codes from hospital discharge abstracts, or at least two ICD9/10 codes from physician billing records, in the two years before the index date. We used validated algorithms to identify co-morbidities, when available (Appendix-Tables 1 and 3). Lastly, we identified if the initial TB drug prescription prescriber was licensed as a family physician or another specialist physician.

Statistical analysis

We estimated treatment completion (with 95% confidence intervals) as the number of patients completing treatment divided by the number starting treatment. Patients who switched drugs were not considered to have completed treatment. We used Kaplan-Meier curves to plot the proportion of people still receiving LTBI treatment across increasing number of doses

dispensed, with curves stratified by LTBI regimen and co-morbidity at treatment start. We estimated severe hepatic adverse event frequency as the proportion of people who started LTBI treatment who had an adverse event during LTBI treatment. Among patients switching regimens, if an adverse event occurred within 30 days after the switch date, it was attributed to the initial regimen.

We calculated descriptive statistics of health system costs during LTBI treatment, in total and stratified by event type, including mean (standard deviation,SD) and median (interquartile range,IQR) of costs per patient starting treatment, percentage of patients with any event, and mean(SD) and median(IQR) number of events per patient. We estimated descriptive statistics of total mean direct costs occurring before, during and after LTBI treatment start, with total costs calculated for each 30-day period up to 3 years before and after the index. We considered costs incurred in the months before the index as baseline co-morbidity markers. To examine whether outcomes differed by LTBI regimen, co-morbidity and age, we stratified treatment completion, severe hepatic adverse events, and mean costs by these factors.

Next, we performed uni- and multi-variable log-binomial regression to compare rifampin and isoniazid treatment completion, since the main outcome variable was binary and a non-rare event[23]. We used generalized estimating equation (GEE) methods with a compound symmetric working correlation structure and robust standard errors to account for patients clustering by treating physicians. We selected variables for inclusion in final multivariable models using backward selection, first including all variables and then removing variables that were not statistically significant at a level of p<0.2. We then performed logistic regression with similar GEE methods to compare severe hepatic adverse event risk. Finally, we performed gamma regression to compare direct costs during LTBI treatment. The gamma distribution is appropriate for skewed cost data, while the log-link guarantees non-negative outcomes and retains the original

(arithmetic mean) scale of the data[24]. We used similar GEE methods and backward selection to select final multivariable models.

Sensitivity analyses included expanding the definition of LTBI treatment to include events and costs occurring up to 90 days after the last drug dispensation, calculating treatment completion assuming all days in-hospital had LTBI drugs dispensed (since inpatient drug dispensation data were missing in the RAMQ database), and excluding TB drug costs from direct cost calculations (since Quebec TB drug costs may not be generalizable to other settings given a higher cost ratio of rifampin to isoniazid compared to Global Drug Fund pricing).

All analyses were completed using SAS version 9.4 (SAS Institute Inc, Cary, NC). This study was funded by a grant through the Canadian Institutes of Health Research. The funder had no role in the study conduct. This study received ethics approval from the McGill University Institutional Review Board (IRB# A06-M 88-09 A).

RESULTS

In total, 9,684 (93%) patients started isoniazid and 864 (7%) started rifampin between 2003 and 2007 (Table 1). There was a slight decrease in the proportion of patients started on isoniazid and a corresponding increase in patients starting rifampin over the time period of the study, though this trend was not statistically significant (p=0.058). LTBI treatment was initiated by a total of 1857 physicians within all 18 health regions in the province (1721 physicians started one or more patients on isoniazid, 263 physicians started one or more patients on rifampin), with a median of 1 patient (range 1-916) per treating physician (data not shown).

Rifampin patients were more likely than isoniazid patients to have had a hospitalization in the previous year, be male, older, and have more co-morbidities at baseline, including cancer, diabetes, renal failure, transplant, and be treated by a physician licensed in a specialty other than

Family Medicine (Table 1). Almost one-third (32%) of rifampin patients were 50 years and older, compared to only 18% of isoniazid patients (Table 1).

Severe hepatic adverse events

In all age groups, the severe hepatotoxic event risk was lower in rifampin than isoniazid patients (Table 2). In total, 15 isoniazid patients (0.2%, 95%CI: 0.1,0.3) had an incident severe hepatic adverse event during LTBI treatment (Table 2), of whom one died, and two received liver transplants (Appendix-Table 4). The five-year age ranges of the two patients who underwent transplants were 20-24 years and 50-54 years, and the patient who died had an age range of 45-49 years. By contrast, only one rifampin patient (0.1%, 95%CI: 0.02,0.6) had a severe hepatic adverse event and did not die nor require liver transplant. This person was aged >65 years and had co-morbidities (Table 2). The median length of hospital stay for a severe hepatic adverse event was 9 days (IQR 4-21 days) (Table 2). In adjusted models the risk of severe hepatotoxic event was higher in 9H patients than 4R patients, though not statistically significant (OR=2.3, 95%CI: 0.3,16.1) (data not shown).

LTBI treatment completion

A total of 392 isoniazid (4.0%, 95%CI: 3.7,4.5) and 13 rifampin (1.5%, 95%CI: 0.8,2.5) patients switched regimens during the LTBI treatment period (data not shown). Overall an estimated 53.5% (95%CI: 50.2, 56.8) of patients completed 4R and 36.9% (95%CI: 35.9, 37.8) completed 9H (Figure 1). Completion was lowest in rifampin-treated patients with co-morbidities (21.9%, 95%CI: 15.8,26.9), versus 29.9% (95%CI: 21.9,32.9) in isoniazid-treated patients with co-morbidities (Figure 1). The proportion of patients stopping treatment was highest in the first month for both regimens (12% of those started on isoniazid, 20% of those

started on rifampin), followed by a lower but consistent dropout proportion each subsequent

month (with exception of rifampin-treated patients with co-morbidities where monthly dropout

frequency was higher). An estimated 59.5% (95%CI: 58.5,60.5) completed 6 months of isoniazid

(Figure 1).

Rifampin patients aged 65 years and older not completing treatment tended to be those

with more co-morbidities and greater healthcare utilization, including 82% having had a

hospitalization in the past year and 65% a hospitalization during LTBI treatment (data not

shown). In multivariable models (Table 3), 4R completion was significantly higher than 9H

(adjusted RR=1.5, 95% CI: 1.3,1.7) after adjustment for age, co-morbidities, and other

confounders. Sensitivity analyses using different completion definitions and of potential bias due

to missing inpatient drug exposure data had a negligible impact on effect estimates (Appendix-

Table 5).

Direct health service use costs

Hospitalizations accounted for the highest mean direct costs per-person starting LTBI

treatment (Table 4). When stratified by age and co-morbidities, the trend was towards higher

mean and median costs of health service use during LTBI treatment in patients with co-

morbidities compared to patients without co-morbidities within the same age group (Table 2).

Median (IQR) health service costs during LTBI treatment were $397 (194, 793) for isoniazid

patients starting treatment and $524 (380, 998) for rifampin patients. Median (IQR) health

service costs excluding TB drugs were $284 (122, 640) and $234 (112, 803) for patients starting

isoniazid and rifampin, respectively (data not shown). Rifampin-treated patients with co-

morbidities also had higher health service costs in the months leading up to treatment start

(Figure 2). In multivariable models (Table 3), 4R costs for direct health service use during LTBI

treatment were lower than 9H (adjusted cost ratio=0.7, 95% CI:0.5,0.9) after adjustment for age, co-morbidities, and other confounders. A sensitivity analysis with TB drug costs excluded led to a larger effect estimate for the adjusted cost ratio of rifampin versus isoniazid (0.6, 95% CI: 0.4,0.8).

DISCUSSION

This study found that the severe hepatic adverse event risk was higher for isoniazid than rifampin across all age groups, and was highest in patients with co-morbidities. Treatment completion was higher for 4R (54%) than 9H (37%), with the lowest completion frequency among people with co-morbidities. Direct health service costs during LTBI treatment were lower for 4R than 9H patients after age and co-morbidities adjustment.

The proportions of people completing treatment for both regimens in our study were lower than reported in other studies[5, 7, 9-13, 25-27]. Much higher completion rates have been reported in randomized clinical trials: Menzies et al (2018) reported 71% completion for 4R and 58% completion for 9H among adults in a phase III trial [7]. But in contrast to our general population cohort, trial participants may be more likely to exhibit 'healthier' behaviours (e.g. following treatment recommendations), and also are likely to be monitored more closely throughout the treatment follow-up period. Completion rates in our study were more comparable to other observational studies comparing the two regimens: Horsburgh et al (2010), for example, in a retrospective observational study of 68 clinics in both the US and Canada found a 55% completion rate for 4R and 31% completion for 9H [27]. Despite differences in completion rates across studies, however, all studies have found 4R completion to be substantially higher than 9H[5, 7, 9-13, 25-27]. As we observed and as has also been previously reported, dropout rates were

highest in the first month[10, 25, 27], followed by steady drop-off rate observed with each subsequent month.

Our study adds to evidence comparing hepatotoxicity risk between isoniazid and rifampin regimens. Similar to findings of a network meta-analysis[28] and clinical trial results[6, 7], we found lower severe hepatotoxicity risk in rifampin than isoniazid patients. Our estimates of hepatotoxicity risk were, however, lower than other published studies comparing the two regimens[6, 7, 9-13, 25]. This likely is because we only included severe hepatotoxicity, defined as a hospitalization directly related to acute hepatotoxicity. Most other published studies have included less severe hepatotoxicity, such as elevated liver enzyme levels or other clinical signs of hepatitis. Menzies et al reported grade 3/4 hepatotoxicity rates of 1.8% and 3.8% for 9H, and 0.3% and 0.7% for 4R in two randomized trials in adults,[6, 7]. Other observational clinic studies have reported hepatotoxicity rates ranging from 1.4% to 2.2% for 9H, and from 0% to 0.7% for 4R[9-11, 13, 25]. However, the frequency of deaths related to INH-associated hepatitis in our study was comparable to older series reported by Snider (1992)[29] and Kopanoff (1978)[30].

Also, similar to systematic review results[31] we found higher hepatotoxicity risk overall in older-aged patients, however this trend was primarily observed among patients with co-morbidities. Among patients without co-morbidities, hepatotoxicity risk with isoniazid was low and there were no hepatotoxic events in patients taking rifampin. Given that concern about isoniazid hepatotoxicity is a barrier in deciding to treat patients for LTBI[31], the findings of low hepatotoxicity risk with rifampin should help increase treatment uptake and completion. Further, our results support previous findings that LTBI treatment for people aged 35 years and older without co-morbidities may be safe with appropriate liver function and symptom monitoring[31].

Contrasting clinical trial results, crude costs were higher for rifampin patients, before and during LTBI treatment. Given that LTBI is asymptomatic and diagnostic work-up would be

similar between the regimens, it is unlikely the cost increase observed before the index date was attributable to LTBI. Rather, it is more likely that rifampin patients were more frequently diagnosed with other co-morbidities which were also risk factors for TB reactivation (and LTBI treatment subsequently initiated). Costs associated with other co-morbidities also likely accounted for some of the non-TB drug costs observed during the LTBI treatment period for the two regimens. Notably, however, after adjustment for numerous co-morbidities as well as older age within the multivariable model for total cost, the cost associated with the rifampin treatment regimen was lower than the cost associated with the isoniazid regimen.

A major strength of our study is that we had complete information on virtually every person in the entire Quebec population who received either isoniazid or rifampin from community pharmacies in the five-year study period. To our knowledge this is the only study to describe use of these two drugs in an entire population, since over 99% of those receiving TB drugs in Quebec were registered in the administrative datasets used. This complete population coverage should have eliminated many of the selection and reporting biases that severely limit the value of many observational studies. And, the inclusion of all persons treated should have overcome the greatest limitation of randomized trials which typically exclude the very young, very old, pregnant women, and persons with important co-morbidities. Hence we believe this data strongly complements evidence from randomized trials; the similar results confirm the critically important safety advantage of rifampin compared to isoniazid-based treatment. In addition the study documents outcomes with hundreds of different providers, many of whom treated few patients, and thus likely less familiar with LTBI management. As well, the large number treated provided greater power to detect rare events, such as liver failure resulting in transplant or death, which are otherwise noted as case reports, making risk estimation difficult.

There are also limitations. Inpatient drug dispensation data were missing, and were only available from community-based pharmacies when paid for by RAMQ (ie. data for non-TB drugs were missing when paid for by private insurance). This could have led to some underestimation of drug costs and LTBI treatment completion, particularly among rifampin patients since a higher proportion were hospitalized during treatment. We relied on hospitalization data to identify patients with severe hepatotoxicity; milder toxicity that did not result in hospitalization may have been much more common, but could not be accurately identified with the administrative health data available. We also limited our analysis of adverse events to hepatotoxicity, thus we would not have captured other potential adverse events associated with these regimens. We recommend that future analyses should also focus on less serious hepatotoxic and other types of adverse events to capture the full adverse event profiles of these drug regimens. We only had drugs dispensed data thus were unable to determine whether all doses were ingested. A further limitation is that rifampin may be prescribed for other conditions. We excluded rifampin prescriptions when given for other known indications, but it is possible that we inadvertently included a few patients for whom rifampin was prescribed for other conditions. This may have underestimated completion since most other conditions require rifampin for less than 4 months, and overestimated costs since these conditions more likely require close follow-up and hospitalization.

Confounding by indication was a further potential bias. We found (similar to other studies[10]) that rifampin patients were more seriously ill at treatment start compared to isoniazid patients, with more co-morbidities, higher hospitalization rates, and higher pre-treatment health service costs. We adjusted for pre-treatment co-morbidities through use of multiple co-morbidity measures. However, residual confounding is still possible, which would underestimate the advantages of 4R. As this was a province-wide study which included all providers in all settings

in the province, incentives and reminder programs may have differed between providers and settings. However we did not have access to this type of data and so do not know if any interventions were in place or if completion rates were higher with specific providers or settings. Lastly, as typical with administrative database studies, misclassification error due to inaccurate data is also possible.

In conclusion, this study found that compared to the 9H regimen, completion was substantially higher with 4R, costs were significantly lower, and severe hepatotoxicity risk, including liver transplant and death was also lower with the 4R regimen. Our findings support use of 4R in preference to 9H for treatment of LTBI.

Table 1: Characteristics of patients initiating treatment for LTBI in Quebec, stratified by initial regimen (H or R) and start year of treatment, 2003-2007 (N=10,559)

Patient characteristics at index date	R (n=875), n (%)	H (n=9684), n (%)	p-value†
Sex- male	421 (48.1%)	4155 (42.9%)	0.003
Age group (years)			<0.001
0-19	63 (7.2%)	2296 (23.7%)	
20-34	309 (35.3%)	3005 (31.0%)	
35-49	220 (25.1%)	2557 (26.4%)	
50-64	147 (16.8%)	1233 (12.7%)	
≥65	136 (15.5%)	593 (6.1%)	
Hospital admission in year before index date			
N (%) of patients	221 (25.4%)	899 (9.3%)	<0.001
Median (IQR) days spent in-hospital	20 (9-41)	5 (2-12)	
Charlson-Deyo co-morbidity level			<0.001
High (score ≥3)	41 (4.7%)	172 (1.8%)	
Moderate (score 1-2)	50 (5.7%)	122 (1.3%)	
TB-related co-morbidities			
HIV/AIDS	5 (0.6%)	103 (1.1%)	0.166
Cancer	50 (5.7%)	301 (3.1%)	<0.001
Diabetes	73 (8.3%)	383 (4.0%)	<0.001
Renal disease	40 (4.6%)	240 (2.5%)	0.002
Solid organ transplant	11 (1.3%)	30 (0.3%)	<0.001
Silicosis	2 (0.2%)	22 (0.2%)	0.993
TNF-alpha inhibitors	1 (0.1%)	31 (0.3%)	0.289
Any psychiatric diagnosis			
Yes	112 (12.8%)	789 (8.2%)	<0.001
Liver disease			
Yes	46 (5.3%)	129 (1.3%)	<0.001
LTBI treatment started by non-family physician*			
Yes	720 (83.2%)	7570 (78.7%)	<0.001
Year of treatment start			
2007	141 (16.1%)	1893 (19.6%)	<0.001
2006	215 (24.6%)	1783 (18.4%)	
2005	194 (22.2%)	1963 (20.3%)	
2004	185 (21.1%)	1961 (20.3%)	
2003	140 (16.0%)	2084 (21.5%)	

Abbreviations: H=Isoniazid; R=rifampin; IQR=interquartile range
* 73% R and 63% H patients treated by specialist in respiratory medicine or infectious diseases
† p-values obtained using chi-square tests

Table 2: Frequencies of LTBI treatment completion and severe hepatic events, and mean direct health system costs during LTBI treatment*, stratified by patient age group and co-morbidity†‡§

	With co-morbidity, by age (years):				No co-morbidity, by age (years):				All patients
	0-19	20-34	35-64	≥65	0-19	20-34	35-64	≥65	
Number of people									
R	8	20	87	106	55	289	280	30	875
H	132	228	356	183	2164	2,777	3,434	410	9,684
Treatment completion, %									
R	28.6	30.0	18.7	16.4	61.6	66.8	63.5	39.4	53.5
H	19.4	22.1	28.2	27.7	33.8	25.3	28.3	34.0	36.9
Severe AE, hepatic, n (%) **									
R	0	0	0	1 (0.9)	0	0	0	0	1 (0.1)
H	0	1 (0.4)	2 (0.6)	2 (1.1)	2 (0.09)	2 (0.07)	5 (0.2)	1 (0.2)	15 (0.2)
TB drug costs, mean $									
R	212	170	225	265	252	257	267	281	256
H	152	74	80	68	182	75	80	77	102
Other costs, mean $									
R	12089	4571	9651	8587	341	223	591	8558	2793
H	2540	5813	13090	25280	556	660	2227	8491	2593

*Patients starting LTBI treatment with H or R in Quebec between 2003-2007 (N=10,559)

† Co-morbidity defined as having one or more hospitalizations in the year before LTBI treatment start

‡ Treatment completion=9H: 270 doses dispensed in 12 months; 4R: 120 doses dispensed in 6 months

§ Costs during LTBI treatment period (from first date with a TB drug dispensed to 30 days after the last TB drug dispensed, limited to a period of up to 12 months for H and 6 months for R). Costs reported in 2011 Canadian dollars (rounded to the nearest dollar). 'Other costs' include all RAMQ-paid costs, except those for TB drugs (i.e., sum of hospitalizations, emergency department (ED) visits, hospital day procedures, physician billing, and non-TB drugs dispensed)

** Included liver transplants (n=2) and hospitalizations ending in death (n=1), all occurring in H patients

Table 3: Predictors of LTBI treatment completion and RAMQ-paid costs for health service use during LTBI treatment period (N=10,559)

Patient and physician characteristics	LTBI treatment completion*			Mean RAMQ-paid costs†		
	# (%) completing	Univariable RR (95% CI)	Multivariable RR (95% CI) ‡	Mean (sd) costs, $	Univariable Cost Ratio (95% CI)	Multivariable Cost Ratio (95% CI) ‡
Starting LTBI regimen						
Rifampin (R)	468 (53.5)	1.4 (1.2-1.7)	1.5 (1.3-1.7)	3048 (10505)	1.1 (0.7, 1.8)	0.7 (0.5, 0.9)
Isoniazid (H)	3570 (36.9)	1.0	1.0	2694 (13539)	1.0	1.0
Sex						
Male	1859 (40.6)	1.1 (1.1-1.2)	1.1 (1.0-1.1)	3574 (16989)	1.7 (1.4, 2.1)	1.2 (0.9, 1.4)
Female	2179 (36.4)	1.0	1.0	2073 (9547)	1.0	1.0
Age group (years)						
0-19	975 (41.3)	1.2 (1.1-1.3)	1.2 (1.1-1.3)	883 (6707)	0.8 (0.5, 1.2)	0.96 (0.7, 1.3)
20-34	1162 (35.1)	1.0	1.0	1091 (8765)	1.0	1.0
35-64	1629 (39.2)	1.2 (1.1-1.3)	1.2 (1.1-1.3)	3297 (14188)	3.1 (2.2, 4.2)	2.3 (1.7, 3.1)
≥65	272 (37.3)	1.2 (1.1-1.4)	1.2 (1.0-1.4)	12832 (28269)	11.7 (8.5, 16.1)	6.3 (4.3, 9.2)
Any hospitalization in year before index						
Yes	316 (28.2)	0.7 (0.7-0.8)	0.7 (0.6-0.8)	11621 (31892)	6.9 (5.7, 8.5)	2.8 (2.2, 3.7)
No	3722 (39.4)	1.0	1.0	1668 (8198)	1.0	1.0
Any Charlson co-morbidities						
Yes	100 (26.0)	0.7 (0.6-0.9)	0.8 (0.6, 0.9)	20641 (43686)	10.1 (7.8,13.0)	-
No	3938 (38.7)	1.0	1.0	2046 (99806)	1.0	
HIV/AIDS						
Yes	55 (50.9)	1.5 (1.2-1.8)	1.5 (1.3-1.9)	17334 (46256)	6.7 (3.9,1 1.7)	5.5 (3.6, 8.6)
No	3983 (38.1)	1.0	1.0	2573 (12448)	1.0	1.0
Cancer						
Yes	106 (30.2)	0.9 (0.7-1.0)	-	19245 (43269)	8.9 (6.7,11.8)	3.1 (2.1, 4.6)
No	3932 (38.5)	1.0		2156 (10462)	1.0	1.0
Diabetes						
Yes	172 (37.7)	1.0 (0.9-1.2)	-	12220 (33187)	5.3 (4.0,7.0)	1.6 (1.2, 2.0)
No	3866 (38.3)	1.0		2295 (11464)	1.0	1.0
Renal failure						

	N (%)*	RR (95% CI)	RR (95% CI)‡	Cost mean (sd)†	RR (95% CI)	RR (95% CI)‡
Yes	108 (38.6)	1.1 (0.9-1.4)	1.2 (0.96, 1.4)	18853 (30224)	8.2 (6.3,10.6)	3.8 (2.9, 4.9)
No	3930 (38.2)	1.0	1.0	2285 (12248)	1.0	1.0
Solid organ transplant						
Yes	18 (43.9)	1.2 (0.9-1.7)	-	22594 (69369)	8.5 (3.3,21.8)	-
No	4020 (38.2)	1.0		2646 (12575)	1.0	
Silicosis						
Yes	11 (45.8)	1.3 (0.8-2.2)	-	5951 (12657)	2.2 (0.9,5.5)	-
No	4027 (38.2)	1.0		2716 (13316)	1.0	
TNF-alpha inhibitors						
Yes	12 (37.5)	1.1 (0.7-1.7)	-	13866 (7921)	5.2 (3.9,6.8)	5.3 (3.7, 7.8)
No	4026 (38.2)	1.0		2690 (13313)	1.0	1.0
Any psychiatric diagnosis						
Yes	305 (33.9)	0.9 (0.8-1.0)	-	7949 (24198)	3.6 (2.8,4.6)	2.5 (1.8, 3.5)
No	3733 (38.7)	1.0		2237 (11682)	1.0	1.0
Physician licensing						
Other specialist	1361 (42.2)	1.1 (1.0-1.2)	1.1 (0.98, 1.2)	2714 (13104)	0.98 (0.7,1.4)	1.3 (1.0, 1.7)
Family physician	712 (32.5)	1.0	1.0	2765 (14239)	1.0	1.0
Year of treatment start						
2007	782 (38.5)	1.1 (0.96-1.2)	1.1 (0.99-1.2)	2559 (14225)	1.0 (0.8,1.5)	-
2006	775 (38.8)	1.1 (0.99-1.2)	1.1 (0.99-1.2)	3031 (11741)	1.2 (0.8,1.6)	
2005	873 (40.5)	1.2 (1.1-1.3)	1.1 (1.0-1.3)	2832 (14448)	1.1 (0.9,1.7)	
2004	814 (37.9)	1.1 (0.96-1.2)	1.1 (0.97-1.2)	2712 (12230)	1.1 (0.7,1.4)	
2003	794 (35.7)	1.0	1.0	2505 (13649)	1.0	

Abbreviations: sd=standard deviation, CI=confidence interval, RR=risk ratio. Missing: treating physician (n=78)

* Treatment completion=9H: 270 doses dispensed in 12 months; 4R: 120 doses dispensed in 6 months

† Costs during LTBI treatment period (from first date with a TB drug dispensed to 30 days after the last TB drug dispensed), limited to a period of up to 1 year for H and 6 months for R. Costs reported in 2011 Canadian dollars. RAMQ-paid costs= sum of hospitalizations+ emergency department (ED) visits+ hospital day procedures+ physician billing + drugs dispensed (TB and non-TB drugs).

‡ Adjusted models including all variables with p<0.2 in multivariable models

Table 4: Patterns and direct costs of health service use by LTBI patients in Quebec (2003-2007) during LTBI treatment period*†

Health service utilization and estimated RAMQ paid costs, per component	Rifampin (n=875)	Isoniazid (n=9684)
Hospitalizations		
Total number of hospitalizations	76	725
Patients with any event, n (%)	59 (6.7%)	493 (5.1%)
Mean # of events/patient (SD) †	1.3 (0.7)	1.5 (0.9)
Median (IQR), max †	1 (1-2), 5	1 (1-2), 6
# days in-hospital per stay, mean (SD) †	12.3 (13.3)	12.2 (24.0)
# days in-hospital per stay, median (IQR) †	9 (4-19)	5 (2-12)
Mean cost, per patient starting treatment (SD)	$1687 (9079)	$1276 (11775)
Emergency department visits		
Total number of ED visits	210	2977
Patients with any event, n (%)	131 (15.0%)	1853 (19.1%)
Mean # of events/patient (SD) †	1.6 (1.7)	1.6 (1.3)
Median (IQR), max †	1 (1-2), 16	1 (1-2), 26
Mean cost, per patient starting treatment (SD)	$44 (158)	$56 (156)
Hospital day procedures		
Total number of procedures	14	311
Patients with any event, n (%)	13 (1.5%)	259 (2.7%)
Mean # of events/patient (SD) †	1.1 (0.3)	1.2 (0.5)
Median (IQR), max †	1 (1-1), 2	1 (1-2), 6
Mean cost, per patient starting treatment (SD)	$3 (25)	$6 (39)
Physician billing		
Total number of physician contacts	6535	86904
Patients with any event, n (%)	820 (93.7%)	8986 (92.8%)
Mean # of events/patient (SD) †	8.0 (12.3)	9.6 (18.8)
Median (IQR), max †	5 (3-8), 1-109	5 (3-10), 1-314
Mean cost, per patient starting treatment (SD)	$426 (1186)	$466 (1271)
Other drugs dispensations ‡		
Total number of other drug dispensations	2950	57522
Patients with any event, n (%)	381 (43.5%)	6146 (63.4%)
Mean # of events/patient (SD) †	7.7 (7.1)	9.3 (12.5)
Median (IQR), max †	6 (2-11), 54	6 (2-10), 34
Mean cost, per patient starting treatment (SD)	$668 (1865)	$793 (3128)
First-line TB drug dispensations		
Total number of TB drug dispensations	2755	60876
Patients with any event, n (%)	875 (100%)	9684 (100%)
Mean # of events/patient (SD) †	3.1 (1.6)	6.3 (3.7)
Median (IQR), max †	4 (2-4), 9	7 (3-9), 50
Mean cost, per patient starting treatment (SD)	$221 (118)	$99 (128)
Total RAMQ-paid costs per patient starting treatment		
Mean (SD)	*$3049 (10505)*	*$2695 (13540)*
Median (IQR)	*$524 (380, 998)*	*$397 (194, 793)*

Abbreviations: SD=standard deviation; IQR=interquartile range

* Total costs during LTBI treatment period (from first date with a TB drug dispensed to 30 days after the last TB drug dispensed, limited to a period of up to 365 days for H and 180 days for R). Costs reported in 2011 Canadian dollars (rounded to the nearest dollar).
† Among patients with one or more events
‡ Other drugs most frequently dispensed, by AHFS drug class: anti-inflammatory agents (acetylsalicylic acid, cox-2 inhibitors), benzodiazapenes, proton-pump inhibitors

References

1.   Lonnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2015;45(4):928-52.

2.   Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2000;49(RR-6):1-51.

3.   Public Health Agency of Canada and Canadian Lung Association/Canadian Thoracic Society. Canadian Tuberculosis Standards, 7th Edition (2014). https://www.canada.ca/en/public-health/services/infectious-diseases/canadian-tuberculosis-standards-7th-edition.html.

4.   Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, et al. European union standards for tuberculosis care. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2012;39(4):807-19.

5.   Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. American journal of respiratory and critical care medicine. 2004;170(4):445-9.

6.   Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Annals of internal medicine. 2008;149(10):689-97.

7.   Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. The New England journal of medicine. 2018;379(5):440-53.

8.   Aspler A, Long R, Trajman A, Dion MJ, Khan K, Schwartzman K, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax. 2010;65(7):582-7.

9.   Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130(6):1712-7.

10.   Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863-70.

11.   Cook PP, Maldonado RA, Yarnell CT, Holbert D. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006;43(3):271-5.

12.   Fresard I, Bridevaux PO, Rochat T, Janssens JP. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. Swiss medical weekly. 2011;141:w13240.

13.   Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009;49(3):424-7.

14.   Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 2004;329(7456):44-7.

15.   Pomey MP, Forest PG, Palley HA, Martin E. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States. The Milbank quarterly. 2007;85(3):469-98.

16.   Myers RP, Leung Y, Shaheen AA, Li B. Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data. BMC health services research. 2007;7:159.

17.   McGill University Health Centre (MUHC). Estimated average costs of inpatient days in McGill University Health Centre (MUHC) hospital. Personal communication (September 2011). 2011.

18.   Santé et Services sociaux Québec. Normes et Practiques de Gestion Circulaire. Tarifs des services rendus en extreme: Listes des taux applicables au 1er mai 2011. Annexe à la circulaire 2011-016 (03.01.42.19). Published 2011-05-01. http://msssa4.msss.gouv.qc.ca/fr/document/d26ngest.nsf/listNum?OpenView

19.   Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2008;12(11):1235-54.

20.   Rubinowicz A, Bartlett G, MacGibbon B, Greenaway C, Ronald L, Munoz M, et al. Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2014;18(12):1449-54.

21.   Pachi A, Bratis D, Moussas G, Tselebis A. Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients. Tuberculosis research and treatment. 2013;2013:489865.

22.   Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical care. 2005;43(11):1130-9.

23.   McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. American journal of epidemiology. 2003;157(10):940-3.

24.   Dodd S, Bassi A, Bodger K, Williamson P. A comparison of multivariable regression models to analyse cost data. Journal of evaluation in clinical practice. 2006;12(1):76-86.

25.   Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2010;14(4):e292-7.

26.   Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2010;14(5):551-9.

27.   Horsburgh CR, Jr., Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB Infection Treatment Acceptance and Completion in the United States and Canada. Chest.137(2):401-9.

28.   Kahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, et al. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and

Systematic Review for the US Preventive Services Task Force. JAMA : the journal of the American Medical Association. 2016;316(9):970-83.

29.   Snider DE, Jr., Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. The American review of respiratory disease. 1992;145(2 Pt 1):494-7.

30.   Kopanoff DE, Snider DE, Jr., Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. The American review of respiratory disease. 1978;117(6):991-1001.

31.   Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2010;14(11):1374-81.

Figure 1: Number of LTBI doses dispensed in Quebec, stratified by starting regimen (H *vs* R) and co-morbidity*

Abbreviations: H=Isoniazid; R=Rifampin

*Co-morbidity defined as having one or more hospitalizations in the year before LTBI treatment start

Figure 2: Estimated mean direct health service use costs for LTBI patients*, stratified by number of months before and after LTBI treatment start and comorbidity†‡

*Patients starting LTBI treatment in Quebec with Isoniazid (H) or Rifampin (R) between 2003-2007
† Co-morbidity defined as one or more hospitalizations in year before LTBI treatment start
‡ Costs reported in 2011 Canadian dollars (rounded to the nearest dollar). Estimated total RAMQ-paid costs= sum of hospitalizations+ emergency department (ED) visits+ hospital day procedures+ physician billing + drugs dispensed (TB and non-TB drugs)

Appendix Table 1: ICD9/10 Diagnostic Codes and American Hospital Formulary Code used for identifying baseline TB-related risk factors, psychiatric diagnosis, and severe hepatic adverse events in RAMQ

ICD9 /ICD10/AHFS/DIN/CCI/CCP codes *	Description
140-172, 174-195.8, 200-208, 238.6, C00-C26, C30-C34, C37-C41, C43, C45-C58, C60-C76, C81-C85, C88, C90-C97	Cancer (malignant neoplasms)†
250, E10-E14	Diabetes†
042-044, V08, B20-B22, B24, Z21, AHF=81808	HIV/AIDS†
403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 582, 583, 585-586, 588, V42.0, V45.1, V56.1, I12.0, I13.1, N03.2-N03.7, N05.2-N05.7, N18, N19, N25.0, Z49.0-Z49.2, Z94.0, Z99.2	Renal Disease†
V42.0,V 42.1, V42.6, V42.7, V42.81,V42.83, V42.84, Z94.0-Z94.4, Z94.6, Z94.8	Solid organ (liver, kidney, heart, lung, pancreas, intestine) or bone marrow transplant
502, J62	Silicosis
DIN= 2242903,2274728,2258595,2244016	Treatment with TNF-alpha inhibitors
290-319, F10-F19	Psychiatric diagnosis
456.0-456.21, 572.2-572.8, I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K71.9, K76.5, K76.6, K76.7	Liver disease†
Hepatic necrosis (570, *K71.1*), toxic hepatitis (573.3, *K71.2, K71.6, K71.9*), hepatic encephalopathy (572.2, *K72.0, K72.9*), liver transplant (CCP=6249; CCI=1OA85)	Hepatotoxicity‡
Leprosy (030, A30); osteomyelitis (730, M86); brucellosis (023, A23); multidrug resistant *Staphylococcus aureus*-MRSA (041.11, 014.12, 038.12, 482.42, A49.0, B95.6, A41.0, G00.3, P36.2, Z22.3, J15.2, L00, P23.2)	Other longer-term RIF indications

*AHFS=American Hospital Formulary Service; DIN=Health Canada Drug Identification Number; CCI=Canadian Classification of Health Interventions; CCP=Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures
†derived from Quan adaptation of the Charlson-Deyo score [22]
‡ derived from Myers (2007)[16]

Appendix Table 2: Summary of direct cost data sources and inputs*

Health service use type	Unit costs	Data source
Hospitalization	$1390	Per diem inpatient room rate (regular ward) at MUHC hospitals for Quebec resident patients[17]
ED visit	$183.08	Hospital billing rate for Quebec resident patients, ambulatory urgent care [18]
Day procedure	$183.08	Hospital billing rate for Quebec resident patients, minor day surgery in operating room[18]
Physician visit	Exact values	Actual billed costs paid by RAMQ
Drugs dispensed	Exact values	Actual billed costs paid by RAMQ, including drug cost and pharmacist dispensing fee, minus deductible and co-pay paid by patients

* Costs reported in 2011 Canadian dollars (rounded to the nearest dollar). Actual billed costs used for physician billing and drugs dispensed, adjusted to 2011 dollars using the Consumer Price Index (https://www.bankofcanada.ca/rates/related/inflation-calculator/). MUHC=McGill University Health Centre

Appendix Table 3: Charlson-Deyo Comorbidity Index, Quan Adaptation (ICD9 and ICD10)

ICD-9/ ICD-10 Codes	Description	Weight
410.x, 412.x, I21.x, I22.x, I25.2	Myocardial Infarction	1
428.x, I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5-I42.9, I43.x, I50.x, P29.0	Congestive heart failure	1
443.9, 441.x, 785.4, V43.4, I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9	Peripheral vascular disease	1
430.x-438.x, G45.x, G46.x, H34.0, 160.x-169.x	Cerebrovascular disease	1
290.x, F00.x-F03.x, F05.1, G30.x, G31.1	Dementia	1
490.x-505.x, 506.x, 127.8, 127.9, J04.x-J47.x, J60.x-J67.x, J68.4, J70.1, J70.3	Chronic pulmonary disease	1
710.0, 710.1, 710.4, 714.0-714.2, 714.81, 725.x, M05.x, M06.x, M31.5, M32.x-M34.x, M35.1, M35.3, M36.0	Rheumatic disease	1
531.x-534.x	Peptic ulcer disease	1
571.2, 571.4-571.6, B18.x, K70.0-K70.3, K70.9, K71.3-K71.5, K71.7, K73.x, K74.x, K76.0, K76.2-K76.4, K76.2-K76.4, K76.8, K76.9, Z94.4	Mild liver disease	1
250.0-250.3, 250.7, E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, E11.6, E11.8, E11.9, E12.0, E12.1, E12.6, E12.8, E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, E14.1, E14.6, E14.8, E14.9	Diabetes without chronic complication	1
250.4-250.6, E10.2-E10.5, E10.7, E11.2-E11.5, E11.7, E12.2-E12.5, E12.7, E13.2-E13.5, E13.7, E14.2-E14.5, E14.7	Diabetes with chronic complication	2
344.1, 342.x, G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0-G83.4, G83.9	Hemiplegia or paraplegia	2
582.x, 583.x-583.7, 585.x, 586.x, 588.x, I12.0, I13.1, N03.2-N03.7, N05.2-N05.7, N18.x, N19.x, N26.0, Z49.0-Z49.2, Z94.0, Z99.2	Renal disease	2
140.x-172.x, 174.x-195.8, 200.x-208.x, C00.x-C26.x, C30.x-C34.x, C37.x-C41.x, C43.x, C45.x-C58.x, C60.x-C76.x, C81.x-C85.x, C88.x, C90.x-C97.x	Any malignancy, including leukemia and lymphoma	2
456.0-456.21, 572.2-572.8, I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K71.9, K76.5, K76.6, K76.7	Moderate or severe liver disease	2
196.x-199.1, C77.x-C80.x	Metastatic solid tumor	3
042.x-044.x, B20.x, B22.x, B24.x	HIV/AIDS	6

Source: Quan et al [22]

Appendix Table 4: Summary of Severe Hepatic Adverse Events, Quebec, 2003-2007

	Relevant hospital diagnosis or intervention	Diag type*	Hospital dates (in, out)	Primary diagnosis; interventions	Drug	Last drug day	Switch day	Death day	SAE	SAE+ transplant†	SAE+ death†
1	Toxic hepatitis	P	202, 216	Toxic hepatitis	H	204	-	-	Hepatic	-	-
2	Toxic hepatitis	P	22, 34	Toxic hepatitis	H	30	-	-	Hepatic	-	-
3	Toxic hepatitis	P	33, 36	Toxic hepatitis	H	30	30	-	Hepatic	-	-
4	Toxic hepatitis	P	59, 63	Toxic hepatitis	H	58	-	-	Hepatic	-	-
5	Toxic hepatitis	P	106, 145	Toxic hepatitis, Liver transplant	H	61	-	-	Hepatic	Yes	-
6	Toxic hepatitis	P	124, 130	Toxic hepatitis	H	127	-	-	Hepatic	-	-
7	Toxic hepatitis	P	266, 298	Acute hepatic failure (S); Sepsis (death)	H	247		298	Hepatic	-	Yes
8	Toxic hepatitis	P	134, 147	Toxic hepatitis	H	135	-	-	Hepatic	-	-
9	Toxic hepatitis	S	108, 112	Pulmonary eosinophilia (P)	H	90			Hepatic	-	-
10	Toxic hepatitis	S	226, 253	Epilepsy NOS	H	236	-	-	Hepatic	-	-
11	Toxic hepatitis	P	24, 28 & 117, 186	Poisoning by anti-mycobacterials (S)	H	30	-	-	Hepatic	-	-
12	Toxic hepatitis	S	63, 85	Poisoning by anti-mycobacterials (P)	H	90	-	-	Hepatic	-	-
13	Toxic hepatitis	S	31, 39	Poisoning by anti-mycobacterials (S)	R	56	-	-	Hepatic	-	-
14	Toxic hepatitis	P	91, 205	Liver transplant	H	30	Start R at 202	-	Hepatic	Yes	-
15	Toxic hepatitis	P	169, 173	Poisoning by anti-mycobacterials (S)	H	180	-	-	Hepatic	-	-
16	Toxic hepatitis	S	313, 320	Poisoning by anti-mycobacterials (P)	H	330	-	-	Hepatic		

*P=primary; A=acute; S=secondary; H=Isoniazid; R=Rifampin
†The five-year age ranges of the two patients who underwent transplants were 20-24 years and 50-54 years, and the patient who died had an age range of 45-49 years

Appendix Table 5: Sensitivity analyses of relative risk estimates of LTBI treatment completion (INH vs RMP), Quebec, 2003-2007 (n=10,559)

Measures of LTBI treatment completion	Patients completing treatment	
	n	% (95% CI)
Dispensed 100% of doses, on-time (primary analysis)		
4RMP (120 doses/6 months)	468	53.5 (50.2-56.8)
9INH (270 doses/12 months)	3570	36.9 (35.9-37.8)
4RMP:9INH, RR (95% CI)		1.5 (1.3-1.7)*
Dispensed 100% of doses, ever (sensitivity analysis #1)		
4RMP (120 doses)	488	55.7 (52.4-59.0)
9INH (270 doses)	3796	39.2 (38.2-40.2)
4RMP:9INH, RR (95% CI)		1.5 (1.3-1.7)*
Dispensed 100% of doses, ever, and including hospitalizations with discharge within 15 days before index date or admission within 30 days after last drug dispensation date as LTBI treatment days (sensitivity analysis #2) ‡		
4RMP (120 doses)	492	56.2 (52.9-59.5)
9INH (270 doses)	3825	39.5 (38.5-40.5)
4RMP:9INH, RR (95% CI)		1.5 (1.3-1.7)*
Dispensed 100% of doses, on-time, excluding patients with hospitalizations with discharge within 15 days before index date, or admission within 30 days after last drug dispensation date (sensitivity analysis #3)		
4RMP (120 doses/6 months)	446	61.6 (58.1-65.2)
9INH (270 doses/12 months)	3359	37.1 (36.1-38.1)
4RMP:9INH, RR (95% CI)		1.7 (1.5-1.9)*
Dispensed 100% of doses, on-time, excluding patients with switches between LTBI regimens (sensitivity analysis #4)		
4RMP (120 doses/6 months)	471	54.6 (51.3-58.0)
9INH (270 doses/12 months)	3576	38.5 (37.5-39.5)
4RMP:9INH, RR (95% CI)		1.5 (1.3-1.8)*

Abbreviations: RR= risk ratio, CI=confidence interval; RMP=rifampin, INH=isoniazid

* RR's and 95% CIs estimated using log-binomial regression with GEE methods to account for clustering of patients within physicians, adjusted for sex, age group, any Charlson co-morbidities, HIV, physician licensing, and hospitalization in the past year